What's in Biocon Biologics UK Ltd's pipeline?

Biocon Biologics UK Ltd has 3 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Biocon Biologics UK Ltd's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/biocon-biologics-uk-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Biocon Biologics UK Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biocon Biologics UK Ltd pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Target	Area
Stelara	Stelara	marketed	Interleukin-12, Interleukin-23	Immunology
Bmab 1000	Bmab 1000	phase 3
Bmab1200	Bmab1200	phase 3

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Biocon Biologics UK Ltd:

Cite this brief

Drug Landscape (2026). Biocon Biologics UK Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biocon-biologics-uk-ltd. Accessed 2026-05-17.